Pharmatica

In this special Scientific Council Spotlight episode of The Discovery Loop podcast, host Shubhangi Dua, Journalist, Podcast Producer and Podcast Host at Pharmatica.io, sits down with Deepankar Nayak, the CEO of Deep Longevity. Nayak also serves on Pharmatica’s Scientific Council.

Could Biological Ageing Be the Next Big Shift in Drug Discovery?

“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."

In the recent episode of The Clinical Compass podcast, host Shubhangi Dua, Podcast Producer and B2B Journalist, is joined by Dr Amber Hill, Founder and CEO of Research Grid. They talk about how pharmaceutical companies and their leaders should approach the use of AI in clinical trials.

In the recent episode of The Discovery Loop podcast, host Shubhangi Dua, Podcast Producer and B2B Journalist at Pharmatica.io, sat down with Diana Andrade, Founder & Managing Director at RD Privacy and Data Protection Officer (DPO) for Biopharma and Life Sciences. They talk about the current state of data protection regulations and how enterprises can innovate responsibly.

In the recent episode of The Chain Reaction podcast, Nour AlSaleh, Founder and CEO of Veragence Pharma Consultancy, sat down with host Shubhangi Dua, Podcast Producer and B2B Journalist at Pharmatica.io and EM360Tech. AlSaleh shares her expertise on maintaining data integrity in this new era of AI and changing policies.

Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.

In the recent episode of the Digital Pulse podcast, host Shubhangi Dua, Podcast Producer and B2B Journalist, sat down with Lara Masad, an AI and Data Innovation independent consultant, to clarify the key distinctions in AI and machine learning models. Furthermore, Masad explains how pharmaceutical companies benefit from using AI models.

Trisha Pillay speaks with Judit Mora, CEO of Nuumad, on Digital Pulse discussing pharmacy innovation, market access barriers, and new models for faster patient access to healthcare.

Trisha Pillay speaks with Dineshree Naiker, co-founder of Umsebe Healthcare, on Chain Reaction discussing regulatory leadership, pharmaceutical supply chains, and improving patient access to medicines.

Exclusive Pharmatica Content

Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.

Nicole Dale

Digital Measures in Clinical Trials: FDA vs EMA Pathways

Clinician reviewing digital measures in clinical trials on a tablet, illustrating regulatory acceptance of digital health technologies, digital biomarkers, and FDA and EMA qualification pathways for modern clinical research.

Explore how novel digital measures gain regulatory acceptance in clinical trials, comparing FDA-structured pathways with EMA engagement-led frameworks.

Nicole Dale

FDA Draft Guidance on Gene Editing Safety (2026)

DNA double helix illustrating the FDA gene editing draft guidance 2026, highlighting next-generation sequencing (NGS) safety assessment, off-target editing analysis, genomic integrity testing, and regulatory requirements for cell and gene therapy development.

The FDA’s 2026 gene editing draft guidance could change your regulatory strategy. Explore the new NGS requirements for cell and gene editing therapies.

Nicole Dale

Optimising Preclinical Pharmacology for Oncology NMEs

Oncology researcher performing preclinical pharmacology testing for new molecular entities (NMEs), illustrating oncology drug development, translational research, biomarker discovery, and advanced preclinical model optimisation.

Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.

Nicole Dale

FDA 2026 Draft Guidance on Alternatives to Animal Testing

Illustration representing FDA alternatives to animal testing, featuring laboratory research, organ-on-chip technology, genetic science, AI-enabled drug discovery and next-generation pharmaceutical testing methods.

The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.

Nicole Dale

Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.

Trisha Pillay

How Pharmacy Innovation Is Changing Healthcare Delivery

Pharmacy is emerging as a critical but overlooked route to faster patient access. In this episode of Digital Pulse, Judit Mora explains how innovation, digital workflows, and pharmacy-led models can bypass traditional delays in healthcare delivery.

Nicole Dale

Phenotypic Drug Discovery: Beyond the Target

Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.

Nicole Dale

Cell Therapy for Solid Tumours: Current Challenges and New Advances

Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.

Nicole Dale

Why Precision Alone Isn't Enough in Oncology Drug Discovery

Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.

Trisha Pillay

How AI Is Reshaping Clinical Trials in HealthTech

Trisha Pillay speaks with Adriaan Kruger, CEO of nuvoteQ, as they unpack why clinical research is still heavily reliant on paper-based systems in many regions.

Nicole Dale

Drug Discovery and Pharmacoinformatics in 2026

Pharmacoinformatics is redefining drug discovery strategy. This analysis covers the AI platforms, molecular design tools, and regulatory frameworks shaping R&D pipelines in 2026.

Nicole Dale

What 13 Years of Data Shows About Drug Innovation in Psychiatry

From 2012 through 2024, the FDA only approved 22 drugs for the treatment of psychiatric conditions. Pharma R&D teams must rethink development strategies to unstall drug innovation in psychiatry

Content type

Topic

Articles, expert interviews, and insights from life sciences leaders

Could Biological Ageing Be the Next Big Shift in Drug Discovery?

Digital Measures in Clinical Trials: FDA vs EMA Pathways

FDA Draft Guidance on Gene Editing Safety (2026)

Optimising Preclinical Pharmacology for Oncology NMEs

FDA 2026 Draft Guidance on Alternatives to Animal Testing

Reimagine AI-driven Drug Discovery with Pharma Superintelligence

How Pharmacy Innovation Is Changing Healthcare Delivery

Phenotypic Drug Discovery: Beyond the Target

Cell Therapy for Solid Tumours: Current Challenges and New Advances

Why Precision Alone Isn't Enough in Oncology Drug Discovery

How AI Is Reshaping Clinical Trials in HealthTech

Drug Discovery and Pharmacoinformatics in 2026

What 13 Years of Data Shows About Drug Innovation in Psychiatry